537 related articles for article (PubMed ID: 23671215)
1. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
Jang W; Park YJ; Park KG; Yu J
J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
[TBL] [Abstract][Full Text] [Related]
3. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
[TBL] [Abstract][Full Text] [Related]
4. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
5. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of extended-spectrum beta-lactamases and its correlation with clinical laboratory standards institute interpretive criteria for disk diffusion susceptibility testing in enterobacteriaceae isolates in Thaialnd.
Tangkoskul T; Tiengrim S; Onsomang S; Pati N; Aswapokee N; Thamlikitkul V; Chayakulkeeree M
Southeast Asian J Trop Med Public Health; 2012 Nov; 43(6):1461-9. PubMed ID: 23413710
[TBL] [Abstract][Full Text] [Related]
8. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
9. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
Hombach M; Mouttet B; Bloemberg GV
J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
[TBL] [Abstract][Full Text] [Related]
11. Dissemination of transferable CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli in Korea.
Jeong SH; Bae IK; Kwon SB; Lee JH; Song JS; Jung HI; Sung KH; Jang SJ; Lee SH
J Appl Microbiol; 2005; 98(4):921-7. PubMed ID: 15752339
[TBL] [Abstract][Full Text] [Related]
12. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
[TBL] [Abstract][Full Text] [Related]
13. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods.
Steward CD; Rasheed JK; Hubert SK; Biddle JW; Raney PM; Anderson GJ; Williams PP; Brittain KL; Oliver A; McGowan JE; Tenover FC
J Clin Microbiol; 2001 Aug; 39(8):2864-72. PubMed ID: 11474005
[TBL] [Abstract][Full Text] [Related]
14. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
[TBL] [Abstract][Full Text] [Related]
15. [Prevalence of extended-spectrum beta-lactamases in Escherichia coli and Klebsiella pneumoniae from Daejeon].
Ko CS; Sung JY; Koo SH; Kwon GC; Shin SY; Park JW
Korean J Lab Med; 2007 Oct; 27(5):344-50. PubMed ID: 18094599
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam.
Cheng NC; Liu CY; Huang YT; Liao CH; Teng LJ; Hsueh PR
J Antimicrob Chemother; 2012 Jun; 67(6):1413-21. PubMed ID: 22345386
[TBL] [Abstract][Full Text] [Related]
17. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
Zarakolu P; Metan G; Hasçelik G; Akova M
Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
[TBL] [Abstract][Full Text] [Related]
18. Molecular characteristics of extended spectrum beta-lactamases in Escherichia coli and Klebsiella pneumoniae and the prevalence of qnr in Extended spectrum beta-lactamase isolates in a tertiary care hospital in Korea.
Kim MH; Lee HJ; Park KS; Suh JT
Yonsei Med J; 2010 Sep; 51(5):768-74. PubMed ID: 20635454
[TBL] [Abstract][Full Text] [Related]
19. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Picón E; Navarro MD; López-Cerero L; Pascual A;
Clin Microbiol Infect; 2012 Sep; 18(9):894-900. PubMed ID: 21985560
[TBL] [Abstract][Full Text] [Related]
20. Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.
Kohner PC; Robberts FJ; Cockerill FR; Patel R
J Clin Microbiol; 2009 Aug; 47(8):2419-25. PubMed ID: 19494061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
